China Medical System Holdings Limited (00867.HK) Latest Company News

Sep 3, 2026, 10:01 UTC
China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.
Source:
Aug 19, 2026, 07:00 UTC
Elevate acquired Lupl, a legal project management platform backed by CMS, Cooley, and Rajah & Tann Asia, to expand its software business.
Source:
- artificiallawyer.com
Aug 17, 2026, 15:08 UTC
China Medical System Holdings Limited declared an interim dividend of RMB 0.1634 per share for the first half of 2026.
Source:
- aastocks.com
Aug 17, 2026, 15:08 UTC
China Medical System Holdings Limited announced its interim results for the six months ended June 2026, with revenue of RMB 4.501 billion, up 12.5% year-on-year, and net profit of RMB 986 million, up 4.8% year-on-year.
Source:
- aastocks.com
- aastocks.com
Jul 31, 2026, 05:16 UTC
Chengdu Biyang Pharmaceutical Technology Co., Ltd. over-completed a nearly 200 million RMB Series A financing round, co-led by Junlian Capital and Shanghai Biomedical Innovation Transformation Fund, with participation from Kangzhe Pharmaceutical, Fenglei Capital, Shanghai Science and Technology Innovation Fund, and Gangyue Capital, while existing shareholders Yuanjin Venture Capital and Yuansheng Venture Capital increased their stakes, and Xinghan Capital served as financial advisor.
Source:
- finance.sina.cn
Jul 15, 2026, 10:37 UTC
China National Medical Products Administration approved CMS-D017 capsule for clinical trial for age-related macular degeneration indication.
Source:
- finance.sina.cn
- aastocks.com
Jul 13, 2026, 00:30 UTC
Insilico Medicine and China Medical System Holdings announced an additional AI-empowered drug discovery collaboration targeting a central nervous system indication.
Source:
Jun 22, 2026, 11:04 UTC
China Medical System Holdings Limited obtained drug registration certificate for Silevimig Injection (GR1801), a Class 1 innovative bispecific antibody for rabies passive immunization, approved by China's NMPA.
Source:
- globenewswire.com

00867.HK

China Medical System Holdings announced that its subsidiary Demei Pharmaceutical received approval from China's National Medical Products Administration for the new drug application of Opzelura (ruxolitinib cream) to add an indication for mild-to-moderate atopic dermatitis in China.

Elevate acquired Lupl, a legal project management platform backed by CMS, Cooley, and Rajah & Tann Asia, to expand its software business.

China Medical System Holdings Limited declared an interim dividend of RMB 0.1634 per share for the first half of 2026.

China Medical System Holdings Limited announced its interim results for the six months ended June 2026, with revenue of RMB 4.501 billion, up 12.5% year-on-year, and net profit of RMB 986 million, up 4.8% year-on-year.

China National Medical Products Administration approved CMS-D017 capsule for clinical trial for age-related macular degeneration indication.

Insilico Medicine and China Medical System Holdings announced an additional AI-empowered drug discovery collaboration targeting a central nervous system indication.

China Medical System Holdings Limited obtained drug registration certificate for Silevimig Injection (GR1801), a Class 1 innovative bispecific antibody for rabies passive immunization, approved by China's NMPA.